Pages that link to "Q36027044"

The following pages link to The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer (Q36027044):

Displaying 48 items.

• Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. (Q33197385) (← links)
• Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis (Q33779856) (← links)
• Clinical pharmacokinetics of goserelin (Q33991285) (← links)
• Gonadotrophin hormone releasing analogues open new doors in cancer treatment (Q34072910) (← links)
• The use of gonadotrophin-releasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and perimenopausal women (Q35111411) (← links)
• Endocrine therapy for advanced breast cancer: a review (Q35338479) (← links)
• Progestins in breast cancer treatment. A review (Q35651439) (← links)
• GnRH analogs in gynecological oncology: a review (Q35655048) (← links)
• The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer (Q35982031) (← links)
• Goserelin (Zoladex) in premenopausal advanced breast cancer: duration of response and survival (Q35982127) (← links)
• A dose-comparative endocrine-clinical study of leuprorelin in premenopausal breast cancer patients (Q35982146) (← links)
• Growth inhibition observed following administration of an LHRH agonist to a clonal variant of the MCF-7 breast cancer cell line is accompanied by an accumulation of cells in the G0/G1 phase of the cell cycle (Q35984682) (← links)
• A phase II trial of goserelin (Zoladex) in relapsed epithelial ovarian cancer (Q35993536) (← links)
• Gonadotrophin-releasing hormone: physiological significance and relevance to cancer (Q36457995) (← links)
• Anti-gonadotrophin releasing hormone antibodies inhibit the growth of MCF7 human breast cancer xenografts (Q36617852) (← links)
• Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical use in sex hormone-related conditions (Q36650783) (← links)
• Shrinkage of uterine fibroids by preoperative LHRH analogue injection (Q36751333) (← links)
• New endocrine approaches to breast cancer (Q37596607) (← links)
• Current status of endocrine treatment of carcinoma of the breast (Q37908010) (← links)
• New endocrine drugs for treatment of advanced breast cancer (Q37938324) (← links)
• Protective effect of leuprolide acetate on 7,12-dimethylbenz(a)anthracene (DMBA)-induced mammary carcinogenesis in rats (Q38559686) (← links)
• Luteinizing hormone-releasing hormone and its analogues: a review of biological properties and clinical uses (Q39470213) (← links)
• Treatment of a Patient with Severe Menstrual Migraine Using the Depot LHRH Analogue Zoladex (Q39509761) (← links)
• Clinical applications of GnRH analogs (Q39564626) (← links)
• Anti-oestrogens in the treatment of breast and gynaecological cancers (Q39566677) (← links)
• LHRH analogues in the management of uterine fibroids, premenstrual syndrome and breast malignancies (Q39566721) (← links)
• Transdermal iontophoresis. Pharmacokinetic considerations (Q40686130) (← links)
• Hormonal treatment of advanced breast cancer. (Q40931762) (← links)
• Current trials and future directions of the Southwest Oncology Group Breast Cancer Committee (Q41023753) (← links)
• Effects of an androgenic derivative on pre-established mammary tumours chemically induced in the rat (Q41143571) (← links)
• Growth inhibition of human prostate tumor cells by an agonist of gonadotrophin-releasing hormone (Q41354135) (← links)
• LHRH analogues in breast cancer: clever, but do we need them? (Q42383824) (← links)
• Tolerability of hormone therapies for breast cancer: how informative are documented symptom profiles in medical notes for 'well-tolerated' treatments? (Q43614271) (← links)
• Estrogen deprivation in breast cancer. Clinical, experimental, and biological aspects (Q43915990) (← links)
• Adverse effect of tamoxifen with LHRH agonist on oestrogen-receptor-negative mammary carcinoma (Q45184916) (← links)
• Arachidonic acid metabolites mediate the radiation-induced increase in glomerular albumin permeability (Q46870371) (← links)
• Specific low affinity binding sites for gonadotropin-releasing hormone in human endometrial carcinomata (Q52442175) (← links)
• Hormonal therapy of breast cancer (Q60357515) (← links)
• Differential effects of LHRH and somatostatin analogs on human breast cancer (Q67514736) (← links)
• Inhibition of growth of MCF-7 MIII human breast carcinoma in nude mice by treatment with agonists or antagonists of LH-RH (Q67550875) (← links)
• Medical Castration with Zoladex: A Conservative Approach to Premenopausal Breast Cancer (Q67950072) (← links)
• Characteristics and distribution of receptors for [D-TRP6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer (Q69372214) (← links)
• Laparoscopic oophorectomy: a prospective evaluation in pre-menopausal breast cancer with particular reference to incidence and severity of menopausal symptoms (Q71748944) (← links)
• Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: a randomized, controlled trial (Q72282161) (← links)
• Adjuvant therapy of breast cancer (Q72347124) (← links)
• Systemic adjuvant treatment for premenopausal node-negative breast cancer. The International Breast Cancer Study Group (Q73752664) (← links)
• Rational use of agonists and antagonists of luteinizing hormone-releasing hormone (LH-RH) in the treatment of hormone-sensitive neoplasms and gynaecologic conditions (Q73850253) (← links)
• Successful co-treatment with LHRH-agonist for ovarian over-stimulation and cystic formation in premenopausal tamoxifen exposure (Q78244539) (← links)